The United States drug development bottleneck, but also will give China pharmaceutical industry development brings tremendous influence.
10, foreign news, 2006 the United States drug market slows, the United States Food and Drug Administration ( FDA ) in 2006 approved a total of 18 new drugs listed, and the same in 2005, for the past few years minimum.
It is understood, in the 6 years to 2005, the United States is average and annual approved drug in 26, but 2005 and 2006 decreased obviously. In fact, this news as early as in many medical research institutions and industry insiders expected. The United States General Accounting Office ( GAO ) a report pointed out that, in recent years, pharmaceutical enterprise R & D expenditure rising, and the drug market is decreasing year by year.
This, analysts say, leading to " innovation wanes " is partly a result of pharmaceutical manufacturers are attempting to overcome some complex disease, does not mean that the new drug R & D activity slows down. While some American lawmakers argue that, to re-examine the drug development system.
Financial stress is one of the reasons why
" Research and development of new drugs to slow, one reason is that at present the United States medical insurance expense shortage, this means that the United States government will have to be from other tax subsidies in the insufficient part, thereby causing the government financial pressure, so the current American government advocate in order to reduce the burden of government, patients do not use expensive patented drugs, and has been used patent period medicine or generic drugs, this reduces the United States corporate R & D enthusiasm. " A Chinese medicine look forward to people 10 day introduction.
In addition, China pharmaceutical company thinks generally, research and development of new drugs is not only a beautiful look forward to more difficult problems, and gradually becomes all multinational Cor.
" Chemical drug development has been faced with a platform that is beyond doubt. " Chinese Medicine International Exchange Center Director Rui Guozhong expresses to the reporter, chemical research and development is actually from a variety of compounds were screened useful molecules, so developed a new drug screening of new useful material more, the greater the difficulty, coupled with the patients for drug safety concerns, regulatory authorities for approval of new drugs more and more strict, these have resulted in the global drug development bottlenecks.
In the field of research and development of traditional Chinese Medicine
At the same time, Rui Guozhong also pointed out that, along with the international pharmaceutical giants in chemical industry are poor skills, they are going to start a global pharmaceutical innovation resources plundering. An obvious example is the large multinational pharmaceutical companies have R & D center in china.
" Multinational pharmaceutical companies in China engaged in R & D, very main reason is the use value of traditional Chinese medicine and natural plant medicine field advantage. In this case, transnational enterprises enter into the Chinese drug research and development may improve the overall level, but from another point of view, the Chinese medicine resources look at fiercely as a tiger does foreign pharmaceutical companies may also become Chinese Pharma threat. " Rui Guozhong stressed.
